Combination of IMOD™ and Arbidol to increase their immunomodulatory effects as a novel medicine to prevent and cure influenza and some other infectious diseases  by Arastoo, Mahmoud et al.
Journal of Medical Hypotheses and Ideas (2014) 8, 53–56Available online at www.sciencedirect.com
Journal of Medical Hypotheses and Ideas
journal homepage: www.elsevier.com/locate/jmhiREGULAR ARTICLECombination of IMOD and Arbidol
to increase their immunomodulatory eﬀects
as a novel medicine to prevent and cure inﬂuenza
and some other infectious diseases* Corresponding author. Tel./fax: +98 21 76250321 5.
E-mail address: mahmoudarastoo@hotmail.co.uk (M. Arastoo).
2251-7294 ª 2014 Published by Elsevier Ltd. on behalf of Tehran University of Medical Sciences.
URL: www.tums.ac.ir/english/
doi:http://dx.doi.org/10.1016/j.jmhi.2014.02.001
Open access under CC BY-NC-N
Open access under CC BY-NCMahmoud Arastoo a,*, Hamid Reza Khorram Khorshid b, Ramin Radmanesh c,
Farhad Gharibdoust d
a Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Tehran, Iran
b Genetic Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
c Pharmaceutical Management Department, Tehran University of Medical Sciences, Tehran, Iran
d Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, IranReceived 25 August 2013; revised 9 February 2014; accepted 9 February 2014
Available online 28 February 2014KEYWORDS
IMOD;
Arbidol;
Infections;
Inﬂuenza viruses;
ImmunomodulatingAbstract Viral diseases such as inﬂuenza, which are easily transferable from person to person or
even country to country, pose one of the biggest threats to health today. Viruses such as avian inﬂu-
enza viruses (N1H5 and H9N1) have been reported to spread in the present decade and, very
recently, the novel coronavirus that has caused many life-threatening illnesses and deaths all around
the world has received much attention.
To prevent these highly contagious viral infections, we have proposed the combination of
IMOD and Arbidol to increase their immunomodulatory effects as a novel medicine to prevent
and cure inﬂuenza and some other infectious diseases such as hepatitis B and C. On the one hand,
IMOD within the last few years has been proven to safely and effectively increase the life expec-
tancy for human immunodeﬁciency virus (HIV)-infected individuals by increasing CD4 lympho-
cytes. On the other hand, Arbidol, an antiviral agent has been used safely and effectively in the
past two decades to prevent and cure all types of inﬂuenza and ﬂu. Therefore, the combination
of both in a single dosage to further increase CD4 lymphocytes and interferon gamma (IFN-c)
could be a better choice for treatment of viral infections. This proposal tries to provide enough sup-
port and background for approval of a randomized clinical trial by a relevant team of investigators.
ª 2014 Published by Elsevier Ltd. on behalf of Tehran University of Medical Sciences.D license.
-ND license.
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IMOD (Immuno-Modulator Drug), which is a patented her-
bal drug that improves the immune system, is formulated from
three herbal extracts of Tanacetum vulgare, Urtica dioica, and
Rosa canina, which is then enriched with selenium [1]. This
drug is used for the treatment of human immunodeﬁciency
virus (HIV) infection by increasing CD4 lymphocytes [2].
These cells are measured in the blood as CD4 and CD8 counts
[3]. The CD4 count is a reﬂection of immune system efﬁciency:
the lower the CD4 count, the weaker the immune system will
be. If the CD4 count is <200 in a microliter of blood, the per-
son is considered to be infected and is involved with AIDS [4].
In fact, patients with a CD4 count of <400 showed a signiﬁ-
cant increase in their CD4 counts following treatment with
IMOD for 3 months in comparison to those in a control
group who were not treated with IMOD [5]. Therefore, this
viral infection disease can be treated with an increasing num-
ber of CD4 lymphocytes in the blood [6]. In addition, the pres-
ence of selenium as an immune booster and the presence of
ﬂavonoids such as chlorogenic acid, caffeic acid, kaempferol,
esculetin, apigenin, luteolin, rutin, ferulic acid, etc., which have
antioxidant effects, help to remove free radicals and improve
the immune system as well.
On the other hand, Arbidol, which is a synthetic broad-spec-
trum antiviral agent [7], has immunomodulating effects and is
an interferon-inducing agent. Therefore, the agent can improve
CD4 counts [8] as well. Arbidol inhibits the fusion of inﬂuenza
A and B (N1H1, N2H2, N2H3, and avian inﬂuenza viruses of
N1H5 and H9N1) and has the same effect on severe acute respi-
ratory syndrome (SARS) viruses that interact with cell mem-
branes. Additionally, the agent inhibits acute and chronic
hepatitis C virus infection [8,9]. Furthermore, Arbidol has anti-
oxidant properties and is in the category of the least toxic drugs
(LD50 > 4 g/kg) which does not have adverse effects on the
human bodywhen taken orally at the recommended dosages [9].
The hypothesis
We propose that the combination of effects from both natural
and synthetic medicines as described above in a single oral cap-
sule could result in a stronger medicine. In addition, it was
shown in different studies that IMOD can increase interferon
release from host cells signiﬁcantly [2]. One such interferon is
interferon gamma (IFN-c) which is crucial for innate and
adaptive immunity. This is also the case with Arbidol, which
shows interferonogenic activity as well [8]. Therefore, this pro-
vides strong evidence to indicate that IMOD can increase the
efﬁcacy of Arbidol further in the treatment of patients. Conse-
quently, this new idea will produce a novel medicine that
increases CD4 cell numbers, boosts the immune system fur-
ther, and thus will be a better choice to prevent and cure viral
infectious diseases.
Evaluation of hypothesis
The hypothesis will be tested as follows:
1. Initial animal toxicity tests have shown that the drug
is practically nontoxic (unpublished data). Thus, a
human clinical trial will be carried out in randomizedlarge gathering groups. Such a clinical test could be
carried out on individuals who will be participating in
the Hajj pilgrimage to Mecca, where millions of people
could be infected and carry a broad range of different
viruses, should the authorities’ permission become
available to the research team of investigators.
2. A battery of genotoxicity and pharmacokinetic studies
including drug interaction tests for such a novel
medicine will be explored deeply.
3. If the above results are satisfactory, then mass produc-
tion will be organized.
Discussion
After a clinical study for Arbidol in a sample of 50 patients, it
was concluded that all ﬁve doses of 50, 100, 200, 500, and
1000 mg were well tolerated [10]. The same result was achieved
in another similar clinical trial on 66 patients [11]. Therefore,
Arbidol is effective and safe for patients with the above-cited
inﬂuenza types including acute viral upper respiratory infec-
tion (URI). The properties of IMOD, concerning its safety
and efﬁcacy, have been the subject of several studies [2,3]
and review articles [12,13] in animals and humans. In addition,
it is a bonus to indicate the positive function of IMOD
through its antioxidant activity in aged mice [14]. In this study,
it was concluded that IMOD prevents superoxide anion and
free radicals through its total antioxidant power. All these
aforementioned effects from IMOD can be used in the treat-
ment of immunologic disorders. The same results in the safety
and efﬁcacy are expected for the novel medicine; however, it is
anticipated to have a stronger action.
At present, the mixture of IMOD and Arbidol at a labo-
ratory scale has been formulated in a single 500-mg capsule
and a pilot scale is in progress. In this formulation, 120 mg
of IMOD, as an active herbal mixed dried extract, and
100 mg of Arbidol raw material were combined with suitable
common excipients (15 mg talc, 85 mg starch, and 180 mg lac-
tose). The toxicology studies of this novel medicine was carried
out by the investigators in mice and showed practically zero
toxicity for doses ranging from 2 to up to 4 g/kg (unpublished
data). Based on Arbidol itself, a course of 12 capsules twice a
day should be prescribed. Accordingly, the dosage in this study
would be two capsules a day, 6 days per week.
Today, with the discovery of new viruses such as the deadly
‘‘Middle East respiratory syndrome coronavirus’’ (MERS-
CoV) [15,16] in Saudi Arabia, which could potentially spread
all around the world, the importance of such a new hypothesis
becomes much more clear.Conclusion
In this context, we proposed a novel idea to prevent and treat
viral infections such as inﬂuenza diseases. As discussed above,
IMOD has been used successfully within the last few years,
resulting in increased CD4 lymphocyte counts and consequent
improvement of the immune system. Similarly, Arbidol also by
itself has proven within the last two decades to be a safe and
effective drug for the prevention and treatment of ﬂu and inﬂu-
enza. Therefore, with the advantage of both medicines, a stron-
ger choice to prevent and cure not only ﬂu but also some other
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targeted. In a large sample of gatherings such as the Hajj pil-
grimage where millions of Muslims are in close contact while
performing their religious obligations, the viruses can be trans-
ferred with ease by sneezing and coughing. Testing the idea in
several groups of attendees could prove the safety and the efﬁ-
cacy of the above combination in a clinical trial. Such results
will be published and the whole society can beneﬁt, especially
during the ﬂu seasons of the year. This strategy will also help
to stop the spreading of such viruses to other countries. More-
over, the mass production of such a beneﬁcial medicine in dif-
ferent forms such as capsules, tablets, and probably ampoules
are proposed if biological tests prove promising.Overview box
First question: What do we already know about the
subject?
1. IMOD safely and effectively increases the life expec-
tancy for the human immunodeﬁciency virus (HIV)-
infected individuals by increasing the CD4
lymphocytes.
2. Arbidol, as an antiviral agent, prevents and cures all
types of inﬂuenza and ﬂu, and has been used safely
and effectively in the past two decades.
Second question: What does your proposed theory add to
the current knowledge available, and what beneﬁt does it
have?
This hypothesis examines the combination of IMOD
and Arbidol to increase their immunomodulatory effects
as a novel medicine to prevent and cure inﬂuenza and
some other infectious diseases in vitro, in animal preclin-
ical trials, and in human clinical trials. Consequently, in
this combination, the weakness of the agents will be
improved by advantages of both medicines as discussed.
Eventually, CD4 cell numbers will increase further to
obtain a better choice to prevent and cure viral infectious
diseases. This could be achieved by the addition of inter-
feron-inducing activity, broad-spectrum antiviral efﬁ-
ciency, antioxidant activity, and inhibition of the fusion
of inﬂuenza viruses interacting with cell membranes.
Today, because of severe deadly ‘‘Middle East respiratory
syndrome coronavirus’’ (MERS-CoV) that has caused
many life-threatening infections in Saudi Arabia and can
cause a global epidemic, the importance of this hypothesis
becomes much clearer.
The mixture of Arbidol and IMOD is formulated in
single 500-mg capsules (120 mg of active ingredients of
IMOD and 100 mg Arbidol) and demonstrated to be
practically nontoxic in mice with an LD50 > 4 g/kg.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
The hypothesis will be tested ﬁrst in T cells and B cells
in vitro, before testing in animals and then humans who
will be participating in the Hajj pilgrimage to Mecca,
where millions of people could be infected and carry a
broad range of different viruses, should the authorities’
permission become available.Conﬂict of interest
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